

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Advisory Committee (DAC)

Minutes of the Meeting on Wednesday 14 March 2018

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

PRESENT:

Standing Committee members:

Dr Mark Kroese – **Chair**
Mr John Bagshaw
Professor Enitan Carrol
Dr Owen Driskell
Dr Simon Fleming
Professor Steve Halligan
Mr John Hitchman
Dr Michael Messenger
Dr Shelley Rahman Haley
Professor Mark Sculpher
Professor Matt Stevenson
Professor Anthony Wierzbicki

Standing Committee apologies:

Dr Steve Edwards
Dr Jim Gray
Professor Christopher Hyde
Mr Patrick McGinley
Mrs Alexandria Moseley
Dr Dermot Neely
Dr Simon Richards

NICE staff in attendance:

Mark Campbell, Acting Programme Director – Devices and Diagnostics
Rebecca Albrow, Senior Technical Adviser, DAP
Donna Barnes, Project Manager, DAP
Frances Nixon, (Technical lead) Technical Analyst, DAP
Christopher Pomfrett, Technical Adviser, MTEP
Alexandra Sexton, Administrator, DAP

Observing:

Julianah Adegbemiso, Business Analyst, Evidence Resources
Ann Greenwood, Senior Medical Editor, NICE
Ian Mather, Resource Impact Assessment Team (*morning session only*)
Lydia Shears, Public Involvement Adviser, PIP
Lynn Woodward, Assistant Project Manager, CCT (*morning session only*)

1. Introduction to the meeting

The Chair noted that Dr Peter Naylor had retired from the committee and recorded the committee's thanks for all his support and contributions.

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

2. Code of conduct for members of the public attending the meeting

The Chair explained the code of conduct to the members of the public attending this meeting.

3. Any other business

No other business was offered.

4. Minutes from the last Committee meeting

The Committee agreed the minutes from the 8 February 2018 committee meeting.

5. Equality and Diversity

The Chair reminded the Committee to raise any potential equality issues related to the topic under discussion.

Assessment of tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

External Assessment Group (EAG) representatives: School of Health and Related Research (SchARR):

Dr Katy Cooper, Research Fellow
Dr Paul Tappenden, Reader

Specialist Committee members:

Dr John Graham, Consultant Oncologist
Linda Pepper, Lay member
Dr Deirdre Ryan, Consultant Cellular Pathologist
Ursula Van Mann, Lay member
Professor Andrew Wardley, Consultant & MAHSC Professor in Medical Oncology

Specialist Committee members' apologies:

Dr Maria Bramley, Breast Surgeon
Dr Britta Stordal, Consultant Clinical Scientist

PART 1 AND PART 2 (open and closed parts of the meeting)

Part 1 – Open session

The Chair welcomed representatives from Agendia N.V., Genomic Health, Myriad Genetics, NanoString Technologies, and the Royal Marsden Hospital.

There were 14 public attendees.

Committee members had declared relevant interests as follows:

- Dr John Graham declared a non-specific personal financial interest, non-specific non-personal financial interests and non-specific personal non-financial interests; these interests did not preclude him from taking part in the meeting.
- Dr Jim Gray declared a non-specific personal financial interest, and a non-specific personal non-financial interest; these interests did not preclude him from taking part in the meeting.
- Dr Owen Driskell declared a non-specific personal non-financial interest; this interest did not preclude him from taking part in the meeting.
- Dr Patrick McGinley declared a non-specific personal financial interest; this interest did not preclude him from taking part in the meeting.
- Dr Michael Messenger declared non-specific non-personal financial interests; these interests did not preclude him from taking part in the meeting.
- Professor Matt Stevenson declared a specific personal non-financial interest; this interest did not preclude him from taking part in the meeting.
- Professor Anthony Wierzbicki declared a non-personal financial interest; this interest did not preclude him from taking part in the meeting.

The Committee proceeded to discuss the comments made during the public consultation for the assessment of tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10).

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

End of Part 1

Part 2a – closed session

Manufacturer representatives who had submitted additional confidential information were separately invited back into the meeting to discuss this with the committee.

The Chair thanked the manufacturer representatives and they left the meeting.

Part 2b – closed session

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the committee.

End of Part 2

Date, time and venue of next meeting

Tuesday 10 April 2018 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD